Aquatic Capital Management LLC Buys 99,653 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Aquatic Capital Management LLC increased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 131.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 175,553 shares of the biopharmaceutical company's stock after buying an additional 99,653 shares during the quarter. Aquatic Capital Management LLC owned 0.15% of Cytokinetics worth $8,258,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its position in Cytokinetics by 189.8% during the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 374 shares during the last quarter. Retirement Systems of Alabama boosted its position in Cytokinetics by 0.4% during the fourth quarter. Retirement Systems of Alabama now owns 143,495 shares of the biopharmaceutical company's stock valued at $6,750,000 after purchasing an additional 565 shares during the last quarter. Arizona State Retirement System boosted its position in Cytokinetics by 1.9% during the fourth quarter. Arizona State Retirement System now owns 32,366 shares of the biopharmaceutical company's stock valued at $1,522,000 after purchasing an additional 600 shares during the last quarter. Inspire Investing LLC boosted its position in Cytokinetics by 7.8% during the fourth quarter. Inspire Investing LLC now owns 8,504 shares of the biopharmaceutical company's stock valued at $400,000 after purchasing an additional 616 shares during the last quarter. Finally, Centricity Wealth Management LLC acquired a new stake in Cytokinetics during the fourth quarter valued at $29,000.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CYTK. Morgan Stanley set a $67.00 price objective on Cytokinetics in a research report on Friday, March 7th. Bank of America reduced their price target on Cytokinetics from $62.00 to $54.00 and set a "neutral" rating for the company in a research report on Tuesday, April 15th. Needham & Company LLC reaffirmed a "buy" rating and issued a $72.00 price target on shares of Cytokinetics in a research report on Tuesday, April 8th. JMP Securities reaffirmed a "market outperform" rating and issued a $78.00 price target on shares of Cytokinetics in a research report on Thursday, April 10th. Finally, Stifel Nicolaus initiated coverage on Cytokinetics in a research report on Wednesday, January 22nd. They issued a "buy" rating and a $80.00 price target for the company. Two analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $79.13.

Insider Buying and Selling

In related news, EVP Andrew Callos sold 2,886 shares of the firm's stock in a transaction on Monday, April 7th. The stock was sold at an average price of $35.78, for a total value of $103,261.08. Following the completion of the transaction, the executive vice president now directly owns 64,689 shares of the company's stock, valued at $2,314,572.42. This trade represents a 4.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert I. Blum sold 5,000 shares of the firm's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $36.77, for a total value of $183,850.00. Following the completion of the transaction, the chief executive officer now directly owns 422,629 shares of the company's stock, valued at approximately $15,540,068.33. This trade represents a 1.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 93,360 shares of company stock valued at $3,848,445 over the last ninety days. 3.40% of the stock is owned by company insiders.

Cytokinetics Stock Performance

Shares of Cytokinetics stock traded up $0.07 during midday trading on Tuesday, hitting $41.29. The company had a trading volume of 1,074,955 shares, compared to its average volume of 1,608,021. The business's 50 day simple moving average is $41.79 and its two-hundred day simple moving average is $46.97. The stock has a market cap of $4.92 billion, a PE ratio of -7.67 and a beta of 0.94. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. Cytokinetics, Incorporated has a 1-year low of $32.74 and a 1-year high of $68.44.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.29) by $0.03. The company had revenue of $16.93 million during the quarter, compared to analyst estimates of $14.26 million. As a group, equities analysts predict that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.